NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...

Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investor ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo Therapeutics Inc (SGMO) stock saw a decline, ending the day at $1.02 which represents a decrease of $-1.32 or -56.41% from the prior close of $2.34. The stock opened at $1.07 and touched a low ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...

Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A program. While it was another big loss to ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Richmond, Calif.-based Sangamo (SGMO) said late Monday it would regain rights to develop and commercialize a treatment called giroctocogene fitelparvovec, which it had licensed to Pfizer. The ...